Nanobody Based Dual Specific CARs

Recent clinical trials have shown that adoptive chimeric antigen receptor (CAR) T cell therapy is a very potent and possibly curative option in the treatment of B cell leukemias and lymphomas. However, targeting a single antigen may not be sufficient, and relapse due to the emergence of antigen nega...

Descripción completa

Detalles Bibliográficos
Autores principales: De Munter, Stijn, Ingels, Joline, Goetgeluk, Glenn, Bonte, Sarah, Pille, Melissa, Weening, Karin, Kerre, Tessa, Abken, Hinrich, Vandekerckhove, Bart
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5855625/
https://www.ncbi.nlm.nih.gov/pubmed/29385713
http://dx.doi.org/10.3390/ijms19020403

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5855625/
https://www.ncbi.nlm.nih.gov/pubmed/29385713
http://dx.doi.org/10.3390/ijms19020403

Ejemplares similares